Summary

U.S. Interventional Cardiology And Peripheral Market Summary

The U.S. interventional cardiology and peripheral market size was estimated at USD 7.9 billion in 2024 and is projected to reach USD 13.1 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. The growth is driven by the growing burden of cardiovascular and peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology.

The increasing geriatric population, higher rates of diabetes and hypertension, and supportive reimbursement policies further fuel market expansion. As more primary care professionals and specialists adopt proactive screening protocols, referral rates to interventionalists have increased. Integrating preventive care with interventional therapies drives a shift in treatment paradigms, positioning minimally invasive techniques as first-line interventions in many clinical scenarios. This progression continues to support the market's expansion across coronary and peripheral segments.
An aging population's demographic trend is pronounced, affecting interventional cardiology and peripheral care markets. In January 2024, the Population Reference Bureau released a fact sheet highlighting the unprecedented growth of the U.S. population aged 65 and older, projected to increase by 47% by 2050. It also noted the rising racial and ethnic diversity among older Americans, with a significant shift expected by mid-century. Older adults often present with multiple comorbidities that make them less suitable for invasive surgical procedures, increasing reliance on catheter-based solutions. These minimally invasive techniques provide a viable alternative for managing vascular blockages and related complications in high-risk patients, with a focus on maintaining quality of life.

Advancements in interventional cardiology devices are reshaping clinical decision-making and procedural outcomes. Newer generations of stents, balloons, and adjunctive tools are designed to improve precision, reduce complications, and enhance long-term vessel patency. These innovations enable physicians to address increasingly complex lesions and expand the pool of eligible patients. Improved deliverability and trackability have made devices more versatile across challenging anatomies. In January 2024, AngioDynamics received FDA 510(k) clearance for its Auryon XL Radial Access Catheter, designed for treating Peripheral Arterial Disease (PAD). The catheter expands treatment options, reduces bleeding risks, and accelerates recovery by utilizing radial access, offering a safer alternative to femoral access in atherectomy procedures.

The introduction of intravascular imaging tools and physiology-guided assessment techniques has added a layer of procedural accuracy. These tools support better visualization and decision-making during interventions, contributing to higher procedural success rates. In the peripheral space, technologies such as atherectomy systems and drug-coated devices have effectively treated long or calcified lesions with reduced need for repeat interventions. In February 2024, Biotronik and IMDS launched the Micro Rx Rapid Exchange Microcatheter in the U.S. This advanced device enhances guidewire support, offering improved push transfer and a tapered tip for better penetration. Designed for percutaneous coronary interventions, it aims to reduce procedure time and minimize vascular trauma, addressing challenges in complex vascular anatomies.

U.S. Interventional Cardiology And Peripheral Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. interventional cardiology and peripheral market report based on product, and application:
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Interventional Catheters
• Microcatheters
o Support Microcatheters
o Delivery Microcatheters
o Others
• Guidewires
• Peripheral Stents
o Self-expanding
o Balloon-expandable
o Drug-eluting Stents
• Coronary Stents
o Bioabsorbable Stents
o Drug-Eluting Stents
o Bare Metal Stents
• PTCA Balloon Catheters
• Atherectomy Devices
• Chronic Total Occlusion Devices
• Synthetic Surgical Grafts
• Embolic Protection Devices
• IVC Filters
• PTA Balloon Catheters
• Thrombectomy Devices
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Angioplasty
• Congenital Heart Defect Correction
• Thrombectomy
• Valvuloplasty
• Percutaneous Valve Repair
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.3. Competitive Insights
Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Interventional Cardiology and Peripheral Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. U.S. Interventional Cardiology and Peripheral Market: Product Movement Analysis
4.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Interventional Catheters
4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Microcatheters
4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2. Support Microcatheters
4.5.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3. Delivery Microcatheters
4.5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.5.4. Others
4.5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Guidewires
4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Peripheral Stents
4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.7.2. Self-Expanding
4.7.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.7.3. Balloon-Expandable
4.7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.7.4. Drug-Eluting Stents
4.7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.8. Coronary Stents
4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.8.2. Bioabsorbable Stents
4.8.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.8.3. Drug-Eluting Stents
4.8.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.8.4. Bare Metal Stents
4.8.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.9. PTCA Balloon Catheters
4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.10. Atherectomy Devices
4.10.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.11. Chronic Total Occlusion Devices
4.11.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.12. Synthetic Surgical Grafts
4.12.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.13. Embolic Protection Devices
4.13.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.14. IVC Filters
4.14.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.15. PTA Balloon Catheters
4.15.1. Market estimates and forecasts 2021 to 2033 (USD Million)
4.16. Thrombectomy Devices
4.16.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. U.S. Interventional Cardiology and Peripheral Market: Application Movement Analysis
5.3. U.S. Interventional Cardiology and Peripheral Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Angioplasty
5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Congenital Heart Defect Correction
5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Thrombectomy
5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Valvuloplasty
5.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.8. Percutaneous Valve Repair
5.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
5.9. Others
5.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. Key company heat map analysis, 2024
6.4. Company Profiles
6.4.1. B. Braun SE
6.4.1.1. Company overview
6.4.1.2. Financial performance
6.4.1.3. Product benchmarking
6.4.1.4. Strategic initiatives
6.4.2. BD
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Product benchmarking
6.4.2.4. Strategic initiatives
6.4.3. Cardinal Health
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Product benchmarking
6.4.3.4. Strategic initiatives
6.4.4. Medtronic
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Product benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Teleflex Incorporated
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Product benchmarking
6.4.5.4. Strategic initiatives
6.4.6. W. L. Gore & Associates Inc.
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Product benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Cook
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Product benchmarking
6.4.7.4. Strategic initiatives
6.4.8. Boston Scientific Corporation
6.4.8.1. Company overview
6.4.8.2. Financial performance
6.4.8.3. Product benchmarking
6.4.8.4. Strategic initiatives
6.4.9. AngioDynamics
6.4.9.1. Company overview
6.4.9.2. Financial performance
6.4.9.3. Product benchmarking
6.4.9.4. Strategic initiatives
6.4.10. Abbott
6.4.10.1. Company overview
6.4.10.2. Financial performance
6.4.10.3. Product benchmarking
6.4.10.4. Strategic initiatives
6.4.11. OrbusNeich Medical Group Holdings Limited
6.4.11.1. Company overview
6.4.11.2. Financial performance
6.4.11.3. Product benchmarking
6.4.11.4. Strategic initiatives